HEALTH IN CODE
Health in Code is a Spain-based clinical genomics company providing NGS-based diagnostic services, CE-IVD analysis kits, and proprietary bioinformatics software to healthcare professionals across 16 medical specialties in more than 30 countries.
- Company typePrivate
- Founded2020
- HeadquartersA Coruña, Spain
- Headcount101–250
- GTM typeB2B
- OfferingServices
What HEALTH IN CODE does
Health in Code is a Spain-headquartered clinical genomics company that provides genetic diagnostic services, proprietary analysis kits, and bioinformatics software to healthcare professionals across more than 30 countries. Founded in 2006 and reconstituted through a 2020 combination of four entities, the company has evolved from a niche inherited cardiovascular disease laboratory into a multi-specialty clinical genomics provider spanning 16 clinical areas, including cardiology, oncology, neurology, pharmacogenetics, immunology, nephrology, prenatal genetics, and rare-disease diagnostics.
The company operates an integrated NGS-based technology stack anchored in Whole Genome Sequencing, trio whole-exome analysis, PacBio Revio long-read HiFi sequencing, and Olink Explore high-throughput proteomics. Spain's first NovaSeq X Plus installation is in operation. Internally developed software includes the AEMPS-licensed Datagenomics client portal and HiC Mutaciones variant interpretation platform, complemented by the CE-IVD-marked Action PharmaKitDx panel covering 335 pharmacogenes. The company runs authorized laboratories in A Coruña, Valencia, and Málaga, with additional offices in Madrid, Granada, and Lisbon, and maintains channel partner laboratories in Germany and Portugal.
The company pursues a B2B go-to-market targeting cardiologists, neurologists, oncologists, hospital laboratories, and research institutions. Revenue is generated through six streams: in-house laboratory diagnostic services, CE-IVD kit and equipment sales to partner laboratories, expert variant interpretation, clinical-genetic reporting, recurring access to proprietary bioinformatics software under AEMPS healthcare license 8581-PS, and proteomics services. Pricing is quote-based and not publicly disclosed. Health in Code is privately held by private equity sponsors — Alantra Private Equity leads ownership after closing a €155 million healthcare continuation fund in February 2026 anchored by Hayfin Capital Management, with Mérieux Equity Partners acquiring a 20% minority stake through its MP4 buyout fund in the same transaction. Revenue has grown from €24 million to over €50 million, with management and investor partners targeting €100 million within five years.
HEALTH IN CODE firmographics
Firmographics- Name
- HEALTH IN CODE
- Legal name
- HEALTH IN CODE, S.L.
- Website
- https://healthincode.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Health in Code is a Spain-based clinical genomics company providing NGS-based diagnostic services, CE-IVD analysis kits, and proprietary bioinformatics software to healthcare professionals across 16 medical specialties in more than 30 countries.
- Ownership category
- akta.pro rank
HEALTH IN CODE industry classification
Industry- Product category
- Clinical Genetic Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)
- akta.pro secondary industries
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
Keywords
Where HEALTH IN CODE is headquartered
LocationHeadquarters
- HQ city
- A Coruña
- HQ country
- Spain
- HQ region
- Europe
Offices6 records
Markets served
HEALTH IN CODE business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Genetic Diagnostic Laboratory Services: Complete genetic studies performed entirely in company laboratories, from sample receipt to specialized clinical report generation. Services include comprehensive genetic testing across 16 clinical areas including cardiology, oncology, neurology, and rare diseases.
- Genetic Analysis Kits: Development and manufacturing of diagnostic disease kits for use in specialized laboratories. Kits include sequencing reagents, bioinformatics software access, database access, and equipment leasing with full process support and guidance.
- Variant Interpretation Services: Clinical and molecular interpretation of genetic studies performed by partner centers, determining pathogenicity of each variant according to the latest international guidelines.
- Clinical Genetic Reports: Clinical-genetic reports of sequencing results from partner center laboratories, prepared by expert teams of medical specialists and biologists specialized in genetic diagnosis of hereditary diseases.
- Bioinformatics Software Platforms: Access to proprietary software platforms (Datagenomics and HiC Mutaciones) for variant filtering, analysis, and interpretation. Licensed under AEMPS healthcare license.
- Proteomics Services: Olink Explore proteomics services for biomarker discovery and analysis in drug development, clinical research, and basic biological science studies.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
HEALTH IN CODE product offering
Product offeringCore offering
Health in Code provides comprehensive genetic diagnostic services using Next-Generation Sequencing (NGS) and complementary technologies across 16 clinical areas including cardiology, oncology, neurology, and pharmacogenetics. The company combines in-house clinical laboratory testing (Whole Genome Sequencing, Trio Exome, NIPT) with proprietary CE-IVD genetic analysis kits and AEMPS-licensed bioinformatics platforms (Datagenomics, HiC Mutaciones) sold to specialist partner laboratories. Its portfolio also includes Olink Explore proteomics services and PacBio Revio long-read sequencing for research and clinical applications.
Product overview
Health in Code is a clinical genomics company offering an integrated model combining NGS-based diagnostic services, genetic analysis kits, and proprietary bioinformatics tools. The portfolio includes Whole Genome Sequencing (WGS) and Trio Exome services for comprehensive genetic diagnosis, the Genatal non-invasive prenatal test, and Olink Explore proteomics platform for protein biomarker analysis. PacBio Revio long-read sequencing provides third-generation sequencing capabilities. The company operates proprietary software platforms including Datagenomics client portal and HiC Mutaciones bioinformatics software (AEMPS licensed). Analysis kits are available across 16 clinical specialty areas. The company holds subsidiaries Genycell Biotech, Genologica, and Imegen Agro, with international operations spanning 30+ countries.
Differentiator
Problem solved
Functional benefit
Brands
- Genycell Biotech: Biotechnology brand under Health in Code umbrella
- Genologica
- Imegen Agro
- Genatal
- Plushic
- Datagenomics
- HiC Mutations
Products and services
- Whole Genome Sequencing (WGS) Complete genome sequencing service providing comprehensive genetic information for diagnosis of complex genetic diseases, using efficient and accessible methodology. Aimed at healthcare professionals requiring whole-genome-level analysis.
- Trio Exome (Exoma completo en trío) Family trio whole exome sequencing providing the highest diagnostic yield for complex genetic diseases, delivering faster results and more informed clinical decisions for pediatric and complex cases.
- Genatal Non-invasive prenatal test (NIPT) for prenatal genetic screening, offered under the Genatal brand for obstetricians and clinical specialists.
- Olink Explore Proteomics High-throughput proteomics platform using Proximity Extension Assay (PEA) technology combined with NGS for simultaneous quantification of hundreds to thousands of protein biomarkers in body fluids, available as a certified Olink Explore service offering.
- PacBio Revio Long-Read Sequencing Third-generation HiFi long-read sequencing service from PacBio Revio providing precision, scalability and simplicity for comprehensive genomic analysis offered by Health in Code as a certified service provider.
- Datagenomics Proprietary client portal platform for genetic study requests, variant filtering, and results report download, including bioinformatics analysis capabilities. Licensed by AEMPS under license number 8581-PS.
- HiC Mutaciones Proprietary in-house bioinformatics analysis software for genetic variant filtering and interpretation, licensed by AEMPS under license number 8581-PS.
- Analysis Kits Genetic diagnostic test kits for specialized laboratory use across cardiology, oncology, neurology, pharmacogenetics, and other clinical specialties; sold to partner laboratories with bioinformatics software, database access, and equipment support.
- Action PharmaKitDx CE-marked targeted NGS panel covering 335 pharmacogenes for pharmacogenetic testing, delivering >99.3% accuracy, sensitivity, specificity, and positive predictive value with 98% concordance against GeT-RM reference materials across multiple Illumina platforms.
Quantifiable outcome
- Revenue growth from €24M to over €50M, more than doubling under Alantra's investment
- +4 more outcomes
Companies that use HEALTH IN CODE
Customer profileNamed customers5 records
Segments17 records
Ideal customer profiles3 records
HEALTH IN CODE technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature7 records
HEALTH IN CODE partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered minor, core and secondary.
- DLA PiperminorDLA Piper served as legal advisor to Mérieux Equity Partners on the acquisition of a significant minority stake in Health in Code. This was a transactional legal advisory role.
- Genologica MédicacoreHealth in Code acquired Genologica Médica, a Málaga-based genetic diagnostics company specializing in disease prevention, diagnosis, prognosis, and treatment of hereditary or genetic diseases. Both companies operate independently in sales and operations but collaborate in research and development to enhance personalized medicine offerings. Genologica is now one of Health in Code's brands alongside Genycell Biotech and Imegen Agro.
- PacBiocoreTechnology partnership for long-read sequencing using PacBio's Revio platform. Health in Code offers Long-Read Sequencing services leveraging PacBio HiFi technology for precise, scalable, and simple genomic analysis. The company is a certified PacBio service provider.
- OlinkcoreHealth in Code is the first certified Olink Explore Service Provider in Spain, offering proteomics services using Olink's PEA technology combined with NGS for scalable biomarker analysis. Provides access to Olink Explore 3072 and Olink Reveal platforms for drug development, clinical research, and biomarker discovery.
- IlluminacoreTechnology partnership for NGS platforms. Health in Code installed Spain's first NovaSeq X Plus, reaffirming leadership in genomic sequencing capacity and commitment to whole genome studies. Validated pharmacogenetic panel on multiple Illumina platforms.
- German Partner LaboratoriessecondaryStrategic agreements with laboratories in Germany for distribution of Health in Code products and services. Part of the company's international expansion strategy.
- Portuguese Partner LaboratoriessecondaryStrategic agreements with laboratories in Portugal for distribution of Health in Code products and services. The company has a Lisbon office to support these partnerships.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
HEALTH IN CODE competitors and assessment
Company assessmentDirect peers
- Invitae: US-based clinical genetic testing company (now operating under Labcorp) offering NGS-based hereditary disease panels across cardiology, oncology, neurology, and rare diseases. Closely aligned with HIC's specialty medical genetics testing portfolio and integrated kit/software/services model.
- GeneDx: US clinical genomics company (owned by Sema4/Moonlake; went public via SPAC) specializing in rare disease exome and genome sequencing with proprietary interpretation platform. Directly comparable to HIC's trio exome, whole genome sequencing, and clinical variant interpretation services.
- PreventionGenetics: US clinical DNA testing laboratory (acquired by Exact Sciences) offering whole genome sequencing, exome sequencing, and multi-specialty hereditary disease panels. Closely comparable to HIC's WGS/trio exome services and multi-area clinical genetic testing.
- Ambry Genetics: US-based clinical genetic testing laboratory (acquired by Konica Minolta) offering hereditary cancer, cardiology, and rare disease NGS panels. Direct functional peer to HIC's multi-specialty clinical genetic testing services and CE-IVD-grade diagnostic offerings.
- Fulgent Genetics: US-based clinical NGS laboratory offering hereditary cancer, cardiovascular, neurological, and reproductive genetic testing through proprietary bioinformatics platform. Direct peer in the clinical genomics services model with comparable test menu breadth and technology partnerships.
- Eurofins Genomics: European division of Eurofins Scientific offering genomic services including NGS, Sanger sequencing, and bioinformatics to pharma, academic, and clinical customers. A pan-European peer whose footprint overlaps with HIC's 30+ country laboratory services in Europe.
- Centogene: Germany-based clinical genomics company focused on rare disease and hereditary diagnostics with multi-omic analysis (genomics, proteomics, metabolomics). Direct comparator to HIC's specialty diagnostic lab model, CE-IVD products, and rare-disease clinical reporting across European markets.
Broad incumbents
- Synlab: Europe's largest medical diagnostics services provider offering clinical lab testing across geographies and specialties. A broader incumbent whose medical laboratory operations overlap HIC's clinical lab segment though it is not specialized in hereditary genomics.
- Cerba Healthcare: European clinical reference laboratory offering specialty testing in genetics, infectious disease, and clinical pathology across multiple European and African markets. Comparable broad European clinical lab footprint with specialty genomics overlap relevant to HIC's cross-border expansion plans.
- Myriad Genetics: Established US diagnostics company offering hereditary cancer (BRACAnalysis), pharmacogenomic, and prenatal screening tests with broader portfolio reach. Overlaps HIC's oncology, pharmacogenetics (PharmaKitDx), and reproductive/prenatal (Genatal) segments as a wider-portfolio incumbent.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
HEALTH IN CODE social profiles
Digital presenceHEALTH IN CODE compliance and trust
Trust signalCompliance4 records
HEALTH IN CODE financial estimates
Financial estimateRevenue estimate
Valuation estimate
HEALTH IN CODE leadership team
Management profileNumber of profiles
Profiles2 records
HEALTH IN CODE subsidiaries and ownership
Company hierarchySubsidiaries3 records
HEALTH IN CODE funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HEALTH IN CODE M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HEALTH IN CODE
What does HEALTH IN CODE do?
Health in Code provides comprehensive genetic diagnostic services using Next-Generation Sequencing (NGS) and complementary technologies across 16 clinical areas including cardiology, oncology, neurology, and pharmacogenetics. The company combines in-house clinical laboratory testing (Whole Genome Sequencing, Trio Exome, NIPT) with proprietary CE-IVD genetic analysis kits and AEMPS-licensed bioinformatics platforms (Datagenomics, HiC Mutaciones) sold to specialist partner laboratories. Its portfolio also includes Olink Explore proteomics services and PacBio Revio long-read sequencing for research and clinical applications.
Is HEALTH IN CODE a public or private company?
HEALTH IN CODE is a private company. It is classified as private equity controlled and is currently operating.
When was HEALTH IN CODE founded?
HEALTH IN CODE was founded in 2020. It employs 101 to 250 people.
Where is HEALTH IN CODE based?
HEALTH IN CODE is headquartered in A Coruña, Spain, in the Europe region.
How does HEALTH IN CODE make money?
Six revenue lines are on record. Genetic Diagnostic Laboratory Services are the primary driver. The others are genetic Analysis Kits, variant Interpretation Services, clinical Genetic Reports, bioinformatics Software Platforms and proteomics Services.
Who are HEALTH IN CODE's main competitors?
Direct peers on record are Invitae, GeneDx, PreventionGenetics, Ambry Genetics, Fulgent Genetics, Eurofins Genomics and Centogene. Broad incumbents are Synlab, Cerba Healthcare and Myriad Genetics.
Does HEALTH IN CODE have an API?
No public API is recorded for HEALTH IN CODE.
What industry is HEALTH IN CODE in?
HEALTH IN CODE's product category is Clinical Genetic Diagnostics. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 621511 and its SIC code is 8071.